Clinical trial · Interventional
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp
NCT00581425CI-TRIAL-00009148completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imiquimod and Interferon alpha | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treated
- interventionNames
- Biological: Imiquimod and Interferon alpha
Primary outcomes (1)
- measure
- resolution of basal cell carcinoma
- timeFrame
- 2 years
Secondary outcomes (1)
- measure
- resolution of basal cell carcinoma at a lower cost and less inflammation.
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Nodular or superficial basal cell carcinoma on the skin excluding scalp or face Exclusion Criteria: * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.